Advertisement covers EACS 2013

Building a Better HIV Drug: Nano-Formulated Medicines

December 18, 2013


Passive and Active Targeting Opportunities in HIV

Passive and Active Targeting Opportunities in HIV

Because of the smaller particle size of nanomedicines, they can better penetrate and target HIV where it lives, as opposed to the systemic approach that current conventional, oral formulations take, Owen said. With passive targeting, particularly at cellular and tissue sites, there can be size-influenced penetration of nanoparticles into lymph nodes where HIV can be hard to reach.

Additionally, there are active targeting opportunities: For instance, nanomedicines could be armed with special receptors, such as a range of cell-specific protein receptors that target HIV replication-competent cells, or tissue-specific protein receptors that may improve distribution into HIV reservoir sites.

This article was provided by It is a part of the publication The 14th European AIDS Conference (EACS 2013).

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.